NotablePrimary endpoints: details revised at 2 of 2 entriesShow 4 more changesShow less
Trial sites expanded: 14 → 21 locations
Primary and study completion dates: May 15, 2028 to Jun 7, 2028
Secondary endpoints: details revised at 2 of 2 entries
Eligibility criteria expanded, about 3 words
MinorTrial sites expanded: 11 → 14 locationsv6
MinorTrial sites expanded: 7 → 11 locationsv5
MinorStudy sites: 6 to 7v4
MinorTrial sites expanded: 3 → 6 locationsv3
NotableRecruitment opened
Study sites: 1 to 3
Primary and study completion dates: May 14, 2028 to May 15, 2028
Start date changed from estimate of May 27, 2026 to May 28, 2026
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.
The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.